| Date Checked | 2025-12-21 23:26:11 |
|---|
| Graham Number | (PB)2.97 vs (PE)0.00 |
|---|
| Over / Under Value Percentage | -24.24% vs 0.00% |
|---|
| Dividend Yield | 0.00% |
|---|
| Dividend Date | None |
|---|
| Symbol | INO |
|---|
| AssetType | Common Stock |
|---|
| Name | Inovio Pharmaceuticals Inc |
|---|
| Description | Inovio Pharmaceuticals Inc. is a cutting-edge biotechnology company dedicated to developing innovative DNA-based therapeutics aimed at treating a range of diseases, including cancer and infectious diseases such as HPV. Leveraging its proprietary platform, Inovio stands at the forefront of immunotherapy advancements and has cultivated a diverse pipeline of product candidates designed to meet significant unmet medical needs. The firm’s ongoing clinical research initiatives reflect its commitment to innovation and adaptability in the face of evolving health challenges, positioning Inovio for potential growth and long-term value creation in the biopharmaceutical landscape. |
|---|
| CIK | 1055726 |
|---|
| Exchange | NASDAQ |
|---|
| Currency | USD |
|---|
| Country | USA |
|---|
| Sector | HEALTHCARE |
|---|
| Industry | BIOTECHNOLOGY |
|---|
| Address | 660 WEST GERMANTOWN PIKE, PLYMOUTH MEETING, PA, UNITED STATES, 19462 |
|---|
| OfficialSite | https://www.inovio.com |
|---|
| FiscalYearEnd | December |
|---|
| LatestQuarter | 2025-09-30 |
|---|
| MarketCapitalization | 138781000 |
|---|
| EBITDA | -88220528 |
|---|
| PERatio | 0 |
|---|
| PEGRatio | 0 |
|---|
| BookValue | -0.144 |
|---|
| DividendPerShare | None |
|---|
| EPS | -2.72 |
|---|
| RevenuePerShareTTM | 0.005 |
|---|
| ProfitMargin | 0 |
|---|
| OperatingMarginTTM | -492.03 |
|---|
| ReturnOnAssetsTTM | -0.636 |
|---|
| ReturnOnEquityTTM | -3.284 |
|---|
| RevenueTTM | 182340 |
|---|
| GrossProfitTTM | -56648752 |
|---|
| DilutedEPSTTM | -2.72 |
|---|
| QuarterlyEarningsGrowthYOY | 0 |
|---|
| QuarterlyRevenueGrowthYOY | 0.14 |
|---|
| AnalystTargetPrice | 7.63 |
|---|
| AnalystRatingStrongBuy | 2 |
|---|
| AnalystRatingBuy | 2 |
|---|
| AnalystRatingHold | 2 |
|---|
| AnalystRatingSell | 0 |
|---|
| AnalystRatingStrongSell | 0 |
|---|
| TrailingPE | - |
|---|
| ForwardPE | - |
|---|
| PriceToSalesRatioTTM | 761.12 |
|---|
| PriceToBookRatio | 4.582 |
|---|
| EVToRevenue | 537.45 |
|---|
| EVToEBITDA | -1.094 |
|---|
| Beta | 1.545 |
|---|
| 52WeekHigh | 4.44 |
|---|
| 52WeekLow | 1.3 |
|---|
| 50DayMovingAverage | 2.249 |
|---|
| 200DayMovingAverage | 1.992 |
|---|
| SharesOutstanding | 68703000 |
|---|
| SharesFloat | 53348000 |
|---|
| PercentInsiders | 0.395 |
|---|
| PercentInstitutions | 37.940 |
|---|
| ExDividendDate | None |
|---|
| dateChecked | 2025-12-21 23:26:11 |
|---|
| fresh | 1 |
|---|